Thiamine-responsive megaloblastic anemia syndrome
MONDO:0009575Thiamine-responsive megaloblastic anemia (TRMA) is characterized by a triad of megaloblastic anemia, non-type I diabetes mellitus, and sensorineural deafness.
Also known as: Rogers syndrome, THMD1, TRMA, thiamine metabolism dysfunction syndrome 1, thiamine-responsive anemia syndrome, thiamine-responsive megaloblastic anemia syndrome, thiamine-responsive megaloblastic anemia with diabetes mellitus and sensorineural deafness, thiamine-responsive myelodysplasia
13 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New blood treatment could block zika in transfusions
Disease control OngoingThis study tests a special treatment for red blood cells that aims to kill the Zika virus, making transfusions safer. About 692 people who need blood transfusions will receive either treated or standard blood. The goal is to see if the treated blood works just as well and is safe…
Phase: PHASE3 • Sponsor: Cerus Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Does trust shape your workout? new study investigates
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how much people trust institutions (like health organizations) when it comes to advice about physical activity. Researchers will ask 2000 volunteers questions about their trust levels, lifestyle, and background. The goal is to understand what factors influence…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC